Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2015–2019

AFib-TrainNet · EU Training Network on Novel Targets and Methods in Atrial Fibrillation

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2015-09-01 → 2019-08-31
Финансиране от ЕС
4 101 222 €
Участници
11
Схема
MSCA-ITN-ETN

Линиите свързват координатора с партньорите.

Накратко на български

Предсърдното потрепване е сърдечно нарушение, при което се търсят нови биологични мишени и методи за лечение. Това е важно, защото заболяването засяга милиони хора в Европа и натоварва значително здравните системи.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

EU Training Network on Novel Targets and Methods in Atrial Fibrillation

Atrial fibrillation (AF) is a complex and multifactorial disease. It is the most common cardiac electrical disturbance, occurring in 1-2% of the population. AF has rapidly become one of the most important public health problems in developed countries. This is due to its disproportionate effects on the elderly, who are growing in numbers thanks to the ageing population in regions like Europe and North America. More than 6 million Europeans suffer from this arrhythmia and its prevalence is expected to more than double in Europe during the next 40 years due to increased life expectancy. Hence, atrial fibrillation has assumed epidemic proportions. AF is not only dangerous – associated with a twofold increase in mortality – it is also expensive, and places a huge burden on healthcare systems. The European Society of Cardiology estimates that at least 1% of the European healthcare budget is currently spent on AF management, equating around 13.5 billion EUR. Despite this, observers have concluded that available strategies for treating this condition are inadequate. AFib-TrainNet is a European Training Network (ETN), which has been focusing on Novel Targets and Methods in Atrial Fibrillation. This network includes 15 PhD students and a number of European academic and industrial organisations. The involved researchers/biotech companies all provide a unique and highly effective platform enabling research collaboration around discovering and evaluating novel targets and methods for AF treatment. The overall objectives of the AFib-TrainNet program has been to: i) Increase understanding of the underlying mechanisms of AF, ii) develop new research tools and methods to scrutinize AF, iii) evaluate two new pharmacological targets for AF treatment, and iv) train 15 ESRs in multidisciplinary research and outreach within the cardiac field. We have obtained the following goals: i) Through a large number of scientific publications we have revealed a sum of new and highly interesting aspects of atrial fibrillation, ii) developed a number of new research tools spanning from atrial hiPSCs to horses as an AF model, iii) performed a number of successful studies with potential new anti-AF compounds, and iv) finalizing a very broad and high level training program for the 15 ESRs.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The AFib-TrainNet consortium will enable promising young scientists to become excellent research leaders of the future, capable of fighting the challenges that Atrial Fibrillation (AF) presents to the European population. AF is the most common sustained cardiac arrhythmia, occurring in between 1-2% of the general population. More than 6 million Europeans suffer from this arrhythmia and its prevalence is expected to increase by more than two-fold during the next 40 years due to increased life expectancy. Thus, AF is said to assume epidemic proportions. Current options for pharmacological therapy are limited by both low efficacy and side effects, including life‐threatening ventricular arrhythmias and severe extra-cardiac toxicities.A very limited number of novel AF drug therapies have been introduced in the last 20 years. This imbalance reflects a gap in understanding in both how AF develops and how it can be treated, which thereby limits the development of new medicines. Our ambition with the AFib-TrainNet is to fill this gap by producing new knowledge, leading to critical insight into origins and mechanisms of sustenance of atrial fibrillation. We will accomplish this by developing novel experimental and computational models recapitulating human AF, and employing these models on two very promising atrial biological targets. Experimental models will be instrumental in improving the understanding AF’s underlying mechanisms, and will, along with clinical data, inform state-of-the-art computational models of human atrial electrophysiology. These new tools will permit fresh insight into the molecular, cellular and electrical mechanisms involved in the progression of healthy atria into an AF state. Our endeavor will deliver results which can be leveraged by the pharmaceutical industry to target AF drug development, and the work accomplished in AFib-TrainNet will thus constitute a beacon in the search for new AF medicine.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз